India Launches Wegovy Injection for Obesity & Heart Risk: Monthly Cost Between ₹17,345–₹26,050
India Launches Wegovy Injection for Obesity & Heart Risk: Monthly Cost Between ₹17,345–₹26,050

India has officially rolled out Wegovy, a prescription weight-loss injection designed to combat obesity and reduce the risk of cardiovascular disease. Manufactured by Denmark-based Novo Nordisk, Wegovy marks a significant development in the country’s fight against rising lifestyle-related health issues.
What Is Wegovy?
Wegovy contains semaglutide, a drug originally used to treat type 2 diabetes. It mimics the action of a natural hormone called GLP-1, which helps regulate appetite and food intake. Administered once a week, the injectable has shown impressive results in clinical trials—helping patients lose substantial weight while also lowering the risk of heart attacks and strokes.
Pricing in India
The treatment comes at a premium, with a monthly cost ranging from ₹17,345 to ₹26,050, depending on dosage. While that may limit its accessibility for some, health experts believe its dual benefit—weight management and heart protection—justifies the investment for high-risk patients.
Who Can Use It?
Wegovy is intended for:
Adults with a Body Mass Index (BMI) of 30 or higher
Individuals with a BMI of 27+ with comorbidities like diabetes, high blood pressure, or cholesterol
Patients at high risk of cardiovascular events
It’s important to note that Wegovy is a prescription-only medicine, and must be used under medical supervision, typically in combination with lifestyle changes like improved diet and regular exercise.
A Global Shift in Obesity Management
Wegovy has already gained significant traction in Western markets, particularly in the US and Europe, where demand has outstripped supply since its debut. Now, with its arrival in India, the drug could reshape how obesity and heart risk are treated in the country—especially among urban populations with sedentary lifestyles.
As India grapples with increasing rates of obesity and cardiovascular illness, Wegovy's launch signals a new era in preventive healthcare, offering a science-backed solution for those struggling to manage weight and heart health through conventional means alone.